Oruka Therapeutics to Participate in Multiple Upcoming Conferences

Oruka Therapeutics (Nasdaq: ORKA) announced its participation and presentations at four healthcare conferences scheduled for November 2026.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Oruka Therapeutics (Nasdaq: ORKA) announced its participation and presentations at four healthcare conferences scheduled for November 2026.

Presentations are scheduled for Guggenheim on November 10 at 11:00 AM EST, Stifel on November 11 at 4:00 PM EST, UBS on November 17 at 4:00 PM GMT, and Jefferies on November 18 at 4:30 PM GMT. Webcasts and replays will be available on Oruka’s investor events website.

Key Terms

hidradenitis suppurativa

1 terms

hidradenitis suppurativa medical

"chronic skin diseases including plaque psoriasis and hidradenitis suppurativa"

A chronic skin disease marked by recurring, painful lumps and tunnels under the skin that often leak and leave scars; it behaves like a slow-burning, recurring infection in areas with many sweat glands. For investors, it matters because the condition has few consistently effective treatments and causes long-term healthcare use, making successful new drugs, devices, or diagnostics potentially high-value opportunities while also carrying clinical-trial, regulatory and reimbursement risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/03/2026 - 07:00 AM EST

MENLO PARK, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis and hidradenitis suppurativa, today announced its participation and presentation at multiple upcoming conferences:

Guggenheim 3^rd Annual Healthcare Innovation Conference
Date: November 10, 2026
Presentation Time: 11:00 AM EST

Stifel 2026 Healthcare Conference
Date: November 11, 2026
Presentation Time: 4:00 PM EST

UBS Global Biopharma Conference
Date: November 17, 2026
Presentation Time: 4:00 PM GMT

Jefferies Global Healthcare Conference
Date: November 18, 2026
Presentation Time: 4:30 PM GMT

Webcasts and replays of Oruka’s presentations will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations.

About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidradenitis suppurativa the greatest possible freedom from their condition by achieving high rates of disease clearance with dosing as infrequently as once or twice a year. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.

Investor Contact:
Alan Lada
(650)-606-7911
alan.lada@orukatx.com